Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension of intravenous vedolizumab in pediatric ulcerative colitis or Crohn's disease
NL-OMON48714Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease, sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events. Planned start Sep 2017; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON48714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48714.